Trial · Interventional
CompletedPhase 2Registry dataSafety Study for Beta Thalassemia Subjects on PTG-300
Short name TRANSCEND
Overview
- Status
- Completed
- Phase
- Phase 2
- Enrollment
- 34 participants (actual)
- Sponsor
- Protagonist Therapeutics, Inc. · Industry
- Design
- Allocation not applicable · Open label (no masking)
- Countries
8 countries
United States, Greece, Lebanon, Malaysia, Thailand, Tunisia, Turkey (Türkiye), United Kingdom
- Start
- 10 May 2019
- Primary completion
- 31 Jul 2020
- Completion
- 31 Jul 2020
- First posted
- 13 Aug 2019
- Last update posted
- 16 Jul 2021
- Conditions
- β-thalassemia · Ineffective Erythropoiesis
Timeline
1 trial · 1 completed
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 2
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
Interventions
- PTG-300Drug
Arms1
Experimental
Interventions
PTG-300
Primary outcomes1
Outcomes the sponsor listed as primary.
Proportion of subjects with side effects and severity of side effects will be tabulated
Time frame · Over two year Period after receiving PTG-300
Registry description
the long-term safety and tolerability of PTG-300 in Beta Thalassemia.
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
Completed trials do not always post results.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- from 12 Years up to 65 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.